This was a relatively quiet regulatory news week when compared to the past few weeks.  Here is my summary of the top stories to follow: The FDA approved Puma Biotechnology’s neratinib for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer. https://www.firstwordpharma.com/node/1488664 The FDA approved Gilead’s VOSEVI, a three-drug combination of[…]